Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1119]

METEOR trial results: Cabozantinib improves advanced kidney cancer survival

Prof Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

METEOR trial results: Cabozantinib improves advanced kidney cancer survival ( Prof Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Highlights of the p-medicine project

Highlights of the p-medicine project ( )

The p-medicine project and ECRIN

Jacques Demotes - ECRIN

The p-medicine project and ECRIN ( Jacques Demotes - ECRIN )

Lenvatinib increases progression free survival when used with everolimus in...

Dr James Larkin - Royal Marsden Hospital, London, UK

Lenvatinib increases progression free survival when used with everolimus in metastatic renal cell carcinoma ( Dr James Larkin - Royal Marsden Hospital, London, UK )

Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer

Dr Simon Chowdhury - Guy's Hospital, London, UK

Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer ( Dr Simon Chowdhury - Guy's Hospital, London, UK )

Developments in clinical trials and health information technology that will...

Dr Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, USA

Developments in clinical trials and health information technology that will improve targeted therapies for patients ( Dr Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, USA )

ASCO 2015: Latest developments in prostate cancer treatment

Prof Cora Sternberg, Prof Noel Clarke, Prof Eleni Efstathiou, Prof Karim Fizazi

ASCO 2015: Latest developments in prostate cancer treatment ( Prof Cora Sternberg, Prof Noel Clarke, Prof Eleni Efstathiou, Prof Karim Fizazi )

Effective adjuvant chemotherapy for high-risk, localised prostate cancer

Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA

Effective adjuvant chemotherapy for high-risk, localised prostate cancer ( Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA )

First effective adjuvant chemotherapy for high-risk, localised prostate cancer

Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA.

First effective adjuvant chemotherapy for high-risk, localised prostate cancer ( Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA. )

Genomic marker predicts anti-PD-1 response in several cancers

Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Genomic marker predicts anti-PD-1 response in several cancers ( Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )

ecancermedicalscience editor's choice for May 2015

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience editor's choice for May 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Prostate cancer and pharmacokinetics: Expert discussion

Prof Axel S. Merseburger and Prof Romano Danesi

Prostate cancer and pharmacokinetics: Expert discussion ( Prof Axel S. Merseburger and Prof Romano Danesi )

More from ecancer